A groundbreaking new treatment regime for bowel cancer patients which involves immunotherapy before surgery has shown remarkable success in improving survival rates and significantly reducing the need for chemotherapy.
Research suggests zero relapses among patients receiving this innovative approach, far exceeding expected outcomes from conventional methods.
